American Capital Advisory’s Revolution Medicines RVMD Stock Holding History

American Capital Advisory’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.69K	Buy	9 +6	+200%	+$876	﹤0.01%	668
2026 Q1	$292	Buy	+3	New	+$303	﹤0.01%	969
2025 Q2	–	Sell	-6	Closed	-$213	–	980
2025 Q1	$213	Buy	+6	New	+$244	﹤0.01%	725

Other funds holding RVMD

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Asset Management One Tokyo, Japan $39B AUM 37.51% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

FAF

Fjarde Ap-fonden Stockholm, Sweden $20.9B AUM 36.93% 1-Year Est. Return

American Capital Advisory's RVMD Position: Q2 2026 in Review

American Capital Advisory increased its Revolution Medicines (RVMD) stake by 200% in Q2 2026, buying an estimated $876 and bringing the position to 9 shares worth $1.69K. The position accounts for ﹤0.01% of the portfolio, ranked #668.

American Capital Advisory first reported a position in RVMD in Q1 2025 and has held it in 3 quarters since. 173 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

American Capital Advisory held 9 shares of Revolution Medicines worth $1.69K as of Q2 2026.
American Capital Advisory bought 6 Revolution Medicines shares in Q2 2026, an estimated $876.
Revolution Medicines made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #668 holding.
American Capital Advisory first reported a position in Revolution Medicines in Q1 2025 and has held it in 3 quarters since.
173 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.